Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751165 | 0.89 | PPARG (0.54) | PPARGEPHX2PPARAMDM2GSK3B | |
| SCHEMBL5751205 | 0.89 | PPARG (0.54) | PPARGEPHX2PPARAMDM2GSK3B | |
| SCHEMBL5752412 | 0.88 | PPARG (0.52) | PPARGEPHX2PPARAMDM2 | |
| SCHEMBL5752947 | 0.87 | EPHX2 (0.52) | PPARGEPHX2PPARAFFAR1 | |
| SCHEMBL5750614 | 0.86 | PPARG (0.51) | PPARGEPHX2PPARAGSK3B | |
| SCHEMBL5750586 | 0.86 | PPARG (0.51) | PPARGEPHX2PPARAMDM2 | |
| SCHEMBL5752346 | 0.85 | GRM4 (0.51) | PPARGEPHX2MDM2FFAR1 | |
| SCHEMBL27686858 | 0.84 | PPARG (0.57) | PPARGEPHX2PPARAFFAR1 | |
| SCHEMBL5753961 | 0.84 | MAPK14 (0.55) | PPARGEPHX2PPARAFFAR1 | |
| SCHEMBL5750773 | 0.81 | PPARG (0.48) | PPARGEPHX2PPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | PPARG 905/4885EPHX2 1434/4885PPARA 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.